Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Despite the improvement of efficacy results with current immunosuppressive regimens (about 15% of incidence of acute rejection), the security schemes used do not show the same results.The most worldwide used regime is tacrolimus, mycophenolate and prednisone. Despite the favorable efficacy results in our population, the use of this combination is associated with higher incidence of viral infections such as cytomegalovirus, and gastrointestinal events, two common causes of hospital readmissions after renal transplantation at our institution.Given this, the investigators propose a study of our own initiative that attends our local needs: identify the best strategy among the therapeutic options available to maintain the result of current effectiveness and improve the safety profile for kidney transplant recipients.This protocol is a prospective, randomized, single center, designed to compare the safety and efficacy of three immunosuppressive regimens: (1) single dose of antithymocyte globulin, reduced exposure to tacrolimus, everolimus starting on day 2 after transplantation and prednisone; ( 2) basiliximab, reduced exposure to tacrolimus, everolimus starting on day 2 after transplantation and prednisone; (3-control group) basiliximab, reduced exposure to tacrolimus, mycophenolate and prednisone.Our hypothesis is that a single dose of antithymocyte globulin or basiliximab induction therapy in combination with low doses of tacrolimus, everolimus and prednisone results in comparable efficacy observed in patients receiving tacrolimus / mycophenolate / prednisone, but with a better safety profile.
To ensure efficacy, the investigators added to the regimes the induction with monoclonal or polyclonal antibody. To improve the toxicities associated with the current scheme, the investigators replace the use of mycophenolate by everolimus and the investigators reduced the dose of tacrolimus.
Patients will be monitored for blood levels of tacrolimus and everolimus to ensure adequate exposure to immunosuppressive agents.
| Condition | Intervention | Phase |
|---|---|---|
|
Cytomegalovirus Infection Renal Transplant Failure Transplant; Complication, Rejection |
Drug: Thymoglobulin Drug: Everolimus Drug: Basiliximabe Drug: mycophenolate sodium Drug: Tacrolimus |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate |
- incidence of CMV infection or disease [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- incidence of treatment failure defined as a composite end-point of BCAR, graft loss, death, loss to follow up. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Thymoglobulin and everolimus
single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
|
Drug: Thymoglobulin
intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
Drug: Everolimus
initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
Drug: Tacrolimus
0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
|
|
Experimental: Basiliximabe and everolimus
basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
|
Drug: Everolimus
initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
Drug: Basiliximabe
days 0 and 4, according to the package insert instructions.
Drug: Tacrolimus
0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
|
|
Active Comparator: Basiliximabe and mycophenolate
basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
|
Drug: Basiliximabe
days 0 and 4, according to the package insert instructions.
Drug: mycophenolate sodium
720 mg BID. This dose will be reduced according to adverse events.
Drug: Tacrolimus
0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
|
Detailed Description:
Primary end-point: The incidence of CMV infection or disease during the first year of transplantation.Secondary main end-point: the incidence of treatment failure defined as a composite end-point of BCAR, graft loss, death, loss to follow up.
The investigators anticipate enrolling 300 patients within 12 months. Only low risk adult candidates for first renal transplants from living or deceased donors will be considered for enrollment. Patients will be excluded if they have been receiving immunosuppressive therapy before transplantation; have received an investigational medication within the past 30 days; have a known contraindication to the administration of antithymocyte globulin; if tested positive for human immunodeficiency virus (HIV); if had had cancer (except nonmelanoma skin cancer) within the previous 2 years. Pregnant women, nursing mothers, and women of childbearing potential who will be not using condoms or oral contraceptives will be excluded. Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II, will also be excluded. Study visits will be performed at pre transplant, days 0, 1, 7, every week up to month 6 and month 12.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- low risk adult candidates for first renal transplants from living or deceased donors
Exclusion Criteria:
- receiving immunosuppressive therapy before transplantation;
- have received an investigational medication within the past 30 days;
- have a known contraindication to the administration of antithymocyte globulin;
- tested positive for human immunodeficiency virus (HIV);
- had had cancer (except nonmelanoma skin cancer) within the previous 2 years;
- Pregnant women, nursing mothers, and women of childbearing potential who will be not using condoms or oral contraceptives will be excluded;
- Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II.
Contacts and Locations| Contact: Cláudia R Felipe, PharmD | 55-11-50878113 | claudiafelipe@medfarm.com.br |
| Contact: Nagilla I Oliveira, PharmD | 55-11-50878113 | nagilla.oliveira@medfarm.com.br |
| Brazil | |
| Hospital do rim e Hipertensao | Recruiting |
| Sao Paulo, Brazil, 04038-002 | |
| Contact: Claudia R Felipe, PharmD 55-11-5087-8113 claudiafelipe@medfarm.com.br | |
| Contact: Nagilla I Oliveira, PharmD 55-11-5087-8113 nagilla.oliveira@medfarm.com.br | |
| Principal Investigator: Helio Tedesco, PhD | |
| Principal Investigator: | Hélio Tedesco, MD | Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos |
More Information
No publications provided
| Responsible Party: | Helio Tedesco Silva Junior, PhD, Hospital do Rim e Hipertensão |
| ClinicalTrials.gov Identifier: | NCT01354301 History of Changes |
| Other Study ID Numbers: | CRAD001ABR18T |
| Study First Received: | May 13, 2011 |
| Last Updated: | July 26, 2012 |
| Health Authority: | Brazil: ANVISA Brazil: CEP-UNIFESP |
Keywords provided by Hospital do Rim e Hipertensão:
|
kidney transplantation thymoglobulin everolimus |
Additional relevant MeSH terms:
|
Cytomegalovirus Infections Herpesviridae Infections DNA Virus Infections Virus Diseases Antilymphocyte Serum Mycophenolate mofetil Everolimus Sirolimus Tacrolimus Mycophenolic Acid Immunosuppressive Agents |
Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antifungal Agents Anti-Infective Agents Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on May 16, 2013